In the last three months, 4 analysts have shared their insights on IGM Biosciences IGMexpressing a variety of opinions ranging from bullish to bearish.
In the table below you’ll find a summary of their recent ratings, revealing changing sentiments over the past 30 days and comparing them to previous months.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 0 | 3 | 1 | 0 | 0 |
| Last 30 days | 0 | 2 | 0 | 0 | 0 |
| 1 million ago | 0 | 1 | 0 | 0 | 0 |
| 2 million ago | 0 | 0 | 0 | 0 | 0 |
| 3 million ago | 0 | 0 | 1 | 0 | 0 |
Providing more in-depth information, the analysts have set 12-month price targets, indicating an average target of $17.50, along with a high estimate of $21.00 and a low estimate of $8.00. This uptrend is evident, with the current average reflecting a 94.44% increase from the previous average price target of $9.00.
Exploring analyst ratings: An in-depth overview
Analysis of recent analyst actions sheds light on financial experts’ perception of IGM Biosciences. The following summary features key analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Far surpass | $21.00 | – |
| Robert Driscoll | Wedbush | Maintains | Far surpass | $20.00 | – |
| Brian Abrahams | RBC Capital | Raise | Far surpass | $21.00 | $9.00 |
| Geoff Meacham | B of A Securities | Announce | Neutral | $8.00 | – |
Key Insights:
- Action taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they “maintain,” “raise,” or “lower” their position, this indicates their reaction to recent developments related to IGM biosciences. This view provides a snapshot of analysts’ perspectives on the current state of the company.
- Assessment: Drilling down into the ratings, analysts assign qualitative values, from “Outperform” to “Underperform”. These ratings communicate expectations for IGM Biosciences’ relative performance compared to the broader market.
- Price targets: Analysts review price target adjustments, providing estimates for the future value of IGM Biosciences. Comparing current and previous targets offers insight into analysts’ evolving expectations.
Analyzing these analyst ratings along with relevant financial metrics can provide a comprehensive view of IGM Biosciences’ market position. Stay informed and make data-driven decisions with the assistance of our ratings table.
Stay updated on the ratings of IGM Biosciences analysts.
If you’re interested in following the news and performance of small-cap stocks, you can start by tracking them here.
Discovering the biosciences of IGM: a closer look
IGM Biosciences Inc is a biotechnology company engaged in the development of therapeutic IgM antibodies for the treatment of cancer, infectious diseases, autoimmune and inflammatory diseases. Its IgM antibody-based technology platform is suitable for the development of T-cell activators, receptor cross-linking agonists and targeted cytokines. Its product candidate, IGM-2323, is a bispecific IgM antibody targeting T cells targeting CD20 and CD3 proteins, IGM-8444, a combination with a chemotherapy agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivers interleukin-15 (IL-15) cytokines to PD-L1-expressing cells for the treatment of patients with solid and hematologic malignancies.
Economic Impact of IGM Biosciences: An Analysis
Market capitalization: Surpassing industry standards, the company’s market capitalization asserts its dominance in terms of size, suggesting a solid market position.
Revenue growth: Over the 3 months, IGM Biosciences showed positive performance, achieving a revenue growth rate of 53.78% as of September 30, 2023. This reflects a substantial increase in the company’s top-line earnings. Compared to other healthcare players, the company faces challenges, achieving a lower growth rate than the average of its peers.
Net margin: IGM Biosciences’ net margin exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive -12178.59% net margin, the company effectively manages costs and achieves strong profitability.
Return on equity (ROE): IGM Biosciences’ ROE is lower than industry averages, suggesting that it is difficult to maximize return on equity. With an ROE of -24.19%, the company may encounter obstacles in achieving optimal financial performance.
Return on Assets (ROA): The company’s ROA is lower than industry benchmarks, signaling potential difficulties in using resources efficiently. With an ROA of -12.98%, the company may face challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.16IGM Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The basis of analyst ratings
Within banking and financial systems, analysts specialize in reporting for specific securities or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically evaluate and rate each stock once a quarter.
Some analysts publish their forecasts for metrics such as growth, earnings and revenue estimates to provide further guidance along with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and only offer their opinions to investors.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.